NCT00651027View on ClinicalTrials.gov

Study To Assess The Impact Of Hepatic Impairment On The Safety, Tolerability And Pharmacokinetics Of Single-Dose 200 Mg Of PF-868554

PHASE1CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

February 29, 2008

Primary Completion Date

September 30, 2008

Study Completion Date

September 30, 2008

Conditions
HEPATITIS C (HCV)
Interventions
DRUG

PF-868554

200 mg, Child-Pugh Class A

DRUG

PF-868554

200 mg, Child-Pugh Class B

DRUG

PF-868554

200 mg, healthy volunteers

Trial Locations (3)

33169

Pfizer Investigational Site, Miami

92801

Pfizer Investigational Site, Anaheim

92804

Pfizer Investigational Site, Anaheim

Sponsors

Lead Sponsor

Pfizer
All Listed Sponsors
lead

Pfizer

INDUSTRY